Masterclass on Tumor Biomarkers (2021)

Welcome Address
V. Georgoulias, F. Koinis

Chairs: L. Kaklamanis, E. Patsea

08.30-08.50 Τhe emerged importance of pathologist beyond the diagnostic workup Ch. Masaoutis
08.50-09.10 Immunocytochemistry as the main tool in cancer diagnosis E. Baliou
09.10-09.30 Emerging immunocytochemical biomarkers in the daily clinical practice E. Lagoudaki
09.30-09.40 General Discussion

Chairs: E. Stathopoulos, E. Saloustros

09.40-10.10 Unfolding the heterogeneity of HER2-positive breast cancer Ch. Magkou
10.10-10.30 Unfolding the molecular heterogeneity of Triple Negative Breast Cancer A. Goussia
10.30-10.50 The need of early detection of PIK3CA mutation in metastatic HR+/HER2- breast cancer
                   K. Antoniadou
10.50-11.00 General Discussion

Coffee Break

Chairs: P. Korkolopoulou, G. Nasioulas

11.20-11.40 The emerged landscape of the tumoral comprehensive molecular profiling using
                   NGS for the identification of relevant biomarkers Z. Saridaki
11.40-12.00 The importance of RNA NGS as a tool for the accurate diagnosis and characterization of
                   the tumors E. Papadopoulou
12.00-12.20 Could the genetic background of cancer patients be used as tumor biomarker?
                    P. Makrythanasis
12.20-12.30 General Discussion

Chairs: E. Lianidou, N. Xenidis

12.30-12.50 An introduction to Liquid Biopsy A. Markou
12.50-13.10 Methodology for Circulating Tumor Cells (CTCs) A. Ntzifa
13.10-13.30 The molecular heterogeneity of CTCs A. Strati
13.30-13.50 The phenotypic heterogeneity of CTCs G. Kallergi
13.50-14.00 General Discussion

Light Lunch

Chairs: A. Koutsopoulos, Th. Tegos

15.00-15.20 The detection and biologic relevance of circulating tumor DNA (ctDNA) E. Kosmidis
15.20-15.40 Assessing the tumor evolution using plasma ctDNA Α. Voutsina
15.40-16.10 The value of ctDNA for the diagnosis and the monitoring of treatment of non-small cell
                   lung cancer F. Papageorgiou
16.10-16.40 Monitoring treatment efficacy in colorectal cancer using ctDNA F.I. Dimitrakopoulos
16.40-16.50 General discussion

Chairs: G. Kallergi, F. Koinis

16.50-17.20 The clinical relevance of CTCs in breast cancer N. Xenidis
17.20-17.50 The clinical relevance of CTCs in prostate cancer Z. Zafeiriou
17.50-18.20 The clinical relevance of CTCs in colorectal cancer (CRC) and cancer of unknown primary
                   site (CUP) T. Londra
18.20-18.40 Exosomes as a potential source of tumor biomarkers E.K. Vetsika
18.40-18.50 General discussion

Coffee Break

Chairs: A. Kotsakis, F. Papageogiou

19.10-19.30 EGFR mutant and ALK rearranged NSCLC E. Kontopodis
19.30-19.50 BRAF, MET, ROS1, RET positive NSCLC Α. Christopoulou
19.50-20.10 KRAS G12C: A new molecular biomarker and target V. Papadopoulos

Chairs: V. Georgoulias, P. Constantoulakis

08.30-08.50 The molecular heterogeneity and emerging biomarkers in colorectal cancer M. Tzardi
08.50-09.10 The molecular landscape and emerging biomarkers in cholangiocarcinoma
                    K. Tsigaridas
09.10-09.30 Emerging molecular biomarkers using NGS in transitional cell carcinoma
                    G. Economopoulou
09.30-09.50 Novel and emerging biomarkers in prostate cancer F. Koinis
09.50-10.00 General discussion

Coffee Break

Chairs: T. Rampias, I. Pateras

10.30-10.50 The clinical utility of HRD in prostate and pancreatic cancer M. Liontos
10.50-11.10 The clinical utility of HRD in ovarian and breast cancer R. Zakopoulou
11.10-11.30 The biological basis and the detection of HRD P. Constantoulakis
11.30-11.40 General discussion

Chairs: D. Papachristou, J. Duran-Moreno

11.40-12.00 The diagnostic algorithm for the detection of NKTR-positive tumors P. Korkolopoulou
12.00-12.20 The NTRK rearrangement as a therapeutic biomarker A. Kyriazoglou
12.20-12.30 General discussion

Chairs: K. Baxevanis, A. Κοtsakis

12.30-12.50 PD-L1 as a biomarker for the treatment with immune checkpoint inhibitors
                    I. Vamvakaris
12.50-13.10 Prognostic and predictive value of TILs I. Pateras
13.10-13.30 The emerging role of tumor mutational burden (TMB) as a new predictive biomarker
                    G. Tsaousis

Antoniadou K.
Presicion Oncology Scientific Lead, SERCE & Greece, Novartis (Hellas) S.A.C.I.
Baliou E.
M.D, MSc, PhD, Pathologist at Athens Medical Center, Athens, Greece
Baxevanis C.
Scientific Director, Cancer Immunology and Immunotherapy Center, Agios Savvas Hospital, Athens, Greece
Christopoulou A.
MD, PhD, Medical Oncologist, Director in the Oncology Unit, Saint Andrews General Hospital of Patras, Greece
Constantoulakis P.
PhD, Molecular Biologist - Geneticist, Scientific Director, GENOTYPOS M.S.A., Greece
Dimitrakopoulos F.I.
MD, BTh, MSc, PhD, Division of Oncology, University Hospital o f Patras & Molecular Oncology Laboratory, University of Patras, Greece
Duran-Moreno J.
MD, MsC, Medical Oncologist
Economopoulou P.
MD, PhD, Consultant Medical Oncologist, 2nd Department of Internal Medicine, Attikon University Hospital, Greece
Georgoulias Vasileios
Emeritus Professor of Medical Oncology, School of Medicine, Uni versity of Crete, Heraklion, Crete
Goussia A.
MD, PhD, Professor of Pathology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Ioannina, Greece
Kaklamanis L.
MD, D.Phil Department of Histopahology, Director Onasssis Cardi ac Surgery Center
Kallergi G.
Assistant Professor of Biochemistry, Department of Biology, University of Patras, Greece
Kontopodis E.
MD, Medical Oncologist, Attending Physician, Venizeleion General Hospital of Heraklion, Greece
Korkolopoulou P.
Professor, First Department of Pathology, National and Kapodistrian University of Athens, Medical School, Athens, Greece
Kosmidis E.
Associate Professor, Laboratory of Physiology, Department of Medicine, Aristotle University of Thessaloniki, Greece
Kotsakis A.
MD, PhD, Associate Professor of Medical Oncology, School of Medicine, University of Thessaly, Director of the Department of Medical Oncology, Gener al University Hospital of Larissa, Larissa
Koutsopoulos A.
MD, PhD, Associate, Professor of Pathology, Department of Pathology, School of Medicine, University of Crete
Kyriazoglou A.
MD, PhD, Medical Oncologist, National & Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, Attikon University Hospital, Athens, Greece
Lagoudaki E.
Pathology Consultant in the Laboratory of P athology of the University General Hospital of Heraklion, Crete
Lianidou E.
Professor of Analytical Chemistry - Clinical Chemistry, Analysis of Circulating Tumor Cells (ACTC) Lab, Dept of Chemistry, University of Athens, Athens, Greece
Londra T.
MSc, Analysis of Circulating Tumor Cells (ACTC) Lab, Dept of Chemistry, National and Kapodistrian University of Athens, Greece
Magkou Ch.
MD, PhD, Department of Pathology, Evaggelismos Hospital, Athens, Greece
Makrythanasis P.
MD, PhD, PD, Assistant Professor, Medical Genetics, Laboratory of Medical Genetics, Medical School, National and Kapodestrian University of Athens, Greece
Markou A.
PhD, Assistant Professor, Lab of Analysis Circulating Tumor Cells (ACTC), Lab of Analytical Chemistry, Dept of Chemistry, National and Kapodistrian University of Athens, Greece
Masaoutis Ch.
Pathologist, Metropolitan General Hospital, Athens, Greece
Nasioulas G.
PhD, Chief Scientific Officer, Genekor Medical S.A., Athens, Greece
Ntzifa A.
MSc, Analysis of Circulating Tumor Cells Lab (ACTC Lab), Department of Chemistry, National and Kapodistrian University of Athens (NKUA), Athens
Papachristou D.
MD, PhD, Consultant Histopathologist, Professor, Univ. of Patras, School of Medicine, Professor (Adj.), Dept. of Pathology, Univ. of Pittsburgh School of Medicine, Pittsburgh, PA, USA, Director, Dept. of, Pathology,’’Olympion’’ General Clinic, Patras, GREECE, Vice President of the Hellenic Group of Sarcomas and Rare Cancers (EOSSO), Athens, Greece
Papadopoulos V.
Medical Oncologist, University Hospital of Larissa, Larissa, Gr eece
Papadopoulou E.
PhD, Group Leader of Molecular Genomics, Genekor Medical S.A, Athens, Greece
Papageorgiou F.
PhD, Biologist, Diagnostics Lead Oncology, AstraZeneca Greece
Pateras I.
Bsc, MD, PhD, Pathologist, Assistant Professor, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Patsea E.
MD, Pathologist, Head of Department, Metropolitan General Hospital, Athens, Greece
Rampias T.
Biomedical Research Foundation Academy Of Athens
Saloustros E.
Assistant Professor of Oncology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa
Saridaki Z.
MD, PhD, Medical Oncologist, Scientific Director of the Oncology Department Asklepios DIAGNOSIS, Asklepeion Crete Clinic, Heraklion, Crete, Greece
Stathopoulos E.
MD, PhD , Pathologist, Professor Emeritus, University of Crete
Strati A.
Postdoctoral Researcher, Analysis of Circulating Tumor Cells lab, Dept of Chemistry, University of Athens, Greece
Tegos Th.
Medical Oncologist, PhD, Evangelismos General Hospital, Athens, Greece
Tsaousis G.
PhD, Group Leader of Bioinformatics, Genekor Medical S.A., Athens, Greece
Tsigaridas K.
Consultant Oncologist, 1st Oncology Department, “Metropolitan” Hospital, Athens, Greece
Tzardi M.
Professor of Pathology, Medical School, Univercity of Crete, Greece
Vamvakaris I.
MD, MSc, PhD, Pathologist,Head of Sotiria Pathology Department, Athens, Greece
Vetsika E.K.
MPhil, PhD, Head of Mass Cytometry Unit, Centre of New Biotech nologies and Precision Medicine, Department of Medicine, School of Health Sciences, Na tional and Kapodistrian University of Athens, Greece
Voutsina A.
MSc, PhD, Postdoctoral Researcher, Greek Genome Center, Biomedical Research, Foundation Academy of Athens (BRFAA), Athens, Greece
Xenidis N.
Associate Professor of Clinical Oncology, Democritus University of Thrace, Greece
Zafeiriou Z.
MD, MSc, Medical Oncologist, Theageneio Anticancer Hospital, Thessaloniki, Greece
Zakopoulou R.
MD, PhD, Medical Oncologist, National and Kapodistrian University of Athens, 2nd Propaedeutic Department of Medicine, A TTIKON University Hospital, Athens, Greece

Αφού έχετε κάνει σύνδεση με τους κωδικούς σας (σε περίπτωση που δεν έχετε κωδικούς ακολουθήστε τη διαδικασία δημιουργίας λογαριασμού), πατήστε το κουμπί "Εγγραφείτε στην εκδήλωση".

Αφού έχετε κάνει σύνδεση με τους κωδικούς σας (σε περίπτωση που δεν έχετε κωδικούς ακολουθήστε τη διαδικασία δημιουργίας λογαριασμού), πατήστε το κουμπί "Εγγραφείτε στην εκδήλωση".

Η καταγραφή του χρόνου παρακολούθησης αναγράφεται στη δεξιά πλευρά της σελίδας της εκδήλωσης που παρακολουθείτε. Η μέτρηση του χρόνου παρακολούθησης ξεκινάει εφόσον έχετε κάνει Subscription και εφόσον η εκδήλωση έχει ξεκινήσει. Η προβολή αυτού του πεδίου, πληροφορεί τον χρήστη για τον χρόνο (minutes) που έχει παρακολουθήσει.

Η εμφάνιση του pop-up window εξυπηρετεί στη διαφάνεια και στην αξιοπιστία των δεδομένων, που τελικά συλλέγονται μετά το πέρας της εκδήλωσης. Η διάρκεια εμφάνισης ενός pop-up window κατά την παρακολούθηση μίας live εκδήλωσης, είναι δύο λεπτά ενώ η επανάληψη εμφάνισης είναι περίπου ανά εξήντα λεπτά. Σε αυτό το διάστημα ο συμμετέχοντας της εκδήλωσης οφείλει να "απαντήσει", επιλέγοντας μία από τις δύο συνθήκες που εμφανίζονται στο pop-up window. Σε διαφορετική περίπτωση, το σύστημα θα διακόψει την καταγραφή του χρόνου παρακολούθησης.

Αφού έχετε κάνει σύνδεση και εγγραφή στην εκδήλωση, μπορείτε να υποβάλετε τις ερωτήσεις σας προς τους ομιλητές στο πεδίο που εμφανίζεται ακριβώς δίπλα στο παράθυρο αναμετάδοσης

Ώρες λειτουργίας Τεχνικής Υποστήριξης:
- καθημερινά 09:00-17:00
- τις ημέρες του event 09:00-21:00
Μπορείτε να επικοινωνήσετε μαζί μας
στο τηλέφωνο +30 210 72 40 039
ή μέσω email support@livetime.gr

 

************************************

 

Technical Support is available:
- everyday 09:00-17:00
- at the day of the event 09:00-21:00
For Technical Support please contact us:
Phone: +30 210 72 40 039
Email: support@livetime.gr

Event Details
  • Start Date
    9 Σεπτεμβρίου, 2021 8:00 πμ
  • End Date
    10 Σεπτεμβρίου, 2021 1:30 μμ
  • Status
    Expired
  • Location
  • Category
Add to Calendar
Share This Event